GENINCODE PLC LS -01

Research GENINCODE PLC LS -01 (9PL) on Bullrun: market cap EUR 5.65M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker9PL
• ExchangeF
• CountryUnited Kingdom
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyEUR
• Market capEUR 5.65M
• Financial periodFY2024
• RevenueEUR 2.70M
• Revenue growth25.0%
• Net income-EUR 4.43M
• Free cash flow-EUR 5.22M
• Gross margin52.8%

Valuation Snapshot

latest market cap is EUR 5.65M.

About GENINCODE PLC LS -01

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient;

Frequently asked questions

What is GENINCODE PLC LS -01's market cap?

GENINCODE PLC LS -01's market capitalization is EUR 5.65M.

What does GENINCODE PLC LS -01 do?

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally.